Massachusetts, USA-based Nona Biosciences has entered into a license agreement with British pharma major AstraZeneca (LSE: AZN).
A subsidiary of Hong Kong’s HBM Holdings (HKEX: 02142), Nona uses its platforms to identify and develop novel biologics.
Using proprietary antibody discovery and development techniques, the company aims to address a range of conditions across oncology, immunology, and infectious diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze